Therapy-related lymphomas in patients with autoimmune diseases after treatment with disease-modifying anti-rheumatic drugs

American Journal of Hematology

Volumn 81, Issue 1, 2006, Pages 5-11

  Au, Wing Yan ^a   Ma, Edmond S K ^a   Choy, Carolyn ^a   Chung, Lap Ping ^a   Fung, Tsz Kin ^a   Liang, Raymond ^a   Kwong, Yok Lam ^a,b  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Autoimmune diseases; Azathioprine; Cyclophosphamide; Methotrexate; Therapy related lymphoma

Indexed keywords

AZATHIOPRINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; MITOXANTRONE; PREDNISOLONE; PROCARBAZINE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CARCINOGENESIS; CLINICAL ARTICLE; DNA METHYLATION; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSURVEILLANCE; LYMPHOMA; LYMPHOMAGENESIS; MALE; MUTAGENESIS; P15 GENE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; BURKITT LYMPHOMA; CELL TRANSFORMATION, VIRAL; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; MALE; MIDDLE AGED; MUTAGENESIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 30444438731     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20508     Document Type: Article

References (11)

1. Liang R, Chan D, Kwong YL, Chan V. Molecular detection of minimal residual disease for patients with leukaemia and lymphoma. Hong Kong Med J 1997;3:195-200.
2. Fung MK, Au WY, Liang R, Srivastava G, Kwong YL. Aberrant promoter methylation in gastric lymphoma. Haematologica 2003;88:231-232.
3. Jaffe ES, Harris NL, Stein H, Vardiman JW (editors). Immunodeficiency- associated lymphoproliferative disorders. In: World Health Organization classification of tumors: tumors of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001. Chapter 9, p 251-271.
4. Cook RC, Connors JM, Gascoyne RD, Fradet G, Levy RD. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation. Lancet 1999;354:1698-2699.
5. Au WY, Fung A, Man C, et al. Aberrant p15 gene promoter methylation in therapy-related myelodysplastic syndrome and acute myeloid leukaemia: clinicopathological and karyotypic associations. Br J Haematol 2003;120:1062-1065.
6. Kwong YL, Au WY, Liang RH. Acute myeloid leukemia after azathioprine treatment for autoimmune diseases: association with -7/7q-. Cancer Genet Cytogenet 1998;104:94-97.
7. Leblond V, Dhedin N, Mamzer Bruneel MF, et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2001;19:772-778.
8. Mariette X, Cazals-Hatem D, Warszawki J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002;99:3909-3915.
9. Baecklund E, Sundstrom C, Ekbom A, et al. Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma. Arthritis Rheum 2003;48:1543-1550.
10. Knipp S, Hildebrandt B, Richter J, Haas R, Germing U, Gattermann N. Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7. Haematologica 2005;90:691-693.
11. Imperato AK, Smiles S, Abramson SB. Long-term risks associated with biologic response modifiers used in rheumatic diseases. Curr Opin Rheumatol 2004;16:199-205.